Crystallization is used as the final separation and purification step in a wide variety of materials from commodity chemicals to specialty chemicals, pharmaceuticals, and foods. It is the final step in more than 70% of small-molecule pharmaceutical manufacture. Purity, crystal size, crystal form (polymorphism), and crystal shape all influence the properties and use of the final product. All of these characteristics can be finessed through manipulation of process conditions, but only because the fundamental science behind crystallization has been investigated thoroughly. PI Myerson studied solution-mediated transformations in systems with polymorphs and pseudopolymorphs and has demonstrated that the driving force for these transformations is the solubility difference between the stable and metastable phases.
Mauricio Futran, a vice president with Bristol-Myers Squibb, states, "Many of Myerson's papers opened up new ways of studying crystallization and provided new insight and understanding of nucleation phenomena with a link to the fundamentals of solution thermodynamics. His work on polymorphism, crystal aging, and metastable solution properties has had great impact on industrial practice."